PRME
Prime Medicine, Inc.
Biotechnology · Healthcare · United States
4.72
close · 2026-10-30
value
11
cheaper than peers11
quality
3
stronger fundamentals3
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, 1 year ago | -15.2% | 41 |
| cash flow yield, latest year | -19.5% | 35 |
| earnings yield, latest year | -28.6% | 35 |
| earnings yield, 1 year ago | -35.0% | 34 |
| cash flow yield, 2 years ago | -20.3% | 33 |
| cash flow yield, 3 years ago | -17.3% | 33 |
| earnings yield, 2 years ago | -46.2% | 32 |
| earnings yield, 3 years ago | -88.8% | 19 |
| price to sales | 210.19× | 9 |
| price to book | 20.98× | 7 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 3.5% | 38 |
| debt to equity | 282.5% | 8 |
| return on equity | -373.3% | 6 |
| operating margin | -3750.9% | 6 |
4 of 4 measures available
Facts
| market cap | $856M |
| free cash flow | -$75.8M |
| employees | 146 |
| first trade | 2022-10-20 |
| next earnings | 2026-08-06 |
| fundamentals updated | 2026-08-28 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.35 | -1.65 | -2.18 | -4.19 |
| free cash flow | -$167.1M | -$130.2M | -$174.1M | -$147.9M |
| net income | -$201.1M | -$195.9M | -$198.1M | -$121.8M |
| revenue | $4.6M | $3.0M | $0 | $0 |
| unusual items | $432,000 | -$485,000 | -$15.9M | -$8.1M |